Clinical aspects of the use of clopidogrel, a new antiplatelet agent

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 2, 1999, Pages 77-82

  Easton, J Donald ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Clopidogrel; Drug interaction; Pharmacodynamics; Pharmacokinetics

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; ACETYLSALICYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ATENOLOL; CLOPIDOGREL; DIGOXIN; DRUG METABOLITE; ESTROGEN; FIBRINOLYTIC AGENT; HEPARIN; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

DRUG INTERACTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TICLOPIDINE;

EID: 0032798130     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
3. Biller J. Number of major vascular events prevented by clopidogrel vs. other cardiovascular therapies. Neurology 1998;50(Suppl 4): A 158(Abst)
4. Morais J (on behalf of the CAPRIE Investigators). Use of concomitant medications in the CAPRIE trial: clopidogrel is unlikely to be associated with clinically significant drug interactions. Eur Heart J 1998;19(Suppl):5(Abst)
5. Guillin MC, Bonnet G, Sissmann J, Necciari J, Dickinson JP. Pharmacodynamics and pharmacokinetics of the novel antiplatelet agent, clopidogrel, in the young and the elderly with and without symptomatic atherosclerosis. Eur Heart J 1996; 17(Suppl):161(Abst)
6. Herbert JM, Frehel D, Vallee E et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993;11:180-198
7. Caplain H, Thebault JJ, Necciari J. Clopidogrel does not affect the pharmacokinetics of theophylline. Semin Thromb Hemost 1999;25(Suppl2):65-68
8. D'Honneur G. Caplain H, Cariou R, et al. Interaction study between clopidogrel and prolonged intravenous heparin administration in young healthy volunteers. Haemostasis 1996;26 (Suppl 3):554(Abst)
9. Savcic M, Goy JJ, Shapira M, et al. Antiaggregatory efficacy and tolerance of clopidogrel in percutaneous transluminal balloon angioplasty. A pilot study. Eur Heart J 1995;16(Suppl):417 (Abst)
10. Bassand JP, Cariou R, Grollier G, et al. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction. Semin Thromb Hemost 1999;25(Suppl 2):69-76
11. Champion GD, Hsii Feng P, Azuma T, et al. NSAID-induced gastrointestinal damage. Drugs 1997;53:6-19
12. Van Hecken A, Depré M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact 1998;4:193-205
13. Peeters PAM, Crijns WJ, Tammings WJ et al. Absence of pharmacokinetic interaction between the novel antiplatelet agent, clopidogrel, and digoxin. Eur Heart J 1996;17(Suppl): 160(Abst)
14. Forbes CD, Beleh JJF, Bridges AB, et al. Pharmacodynamic compatibility of clopidogrel with atenolol and nifedipine co-medication in patients with atherosclerotic disease. Eur Heart J 1996;17(Suppl):160(Abst)
15. McEwen J, Strauch G, Perles P, et al. Clopidogrel bioavailability is unaffected by food or antacids. J Clin Pharmacol 1996; 36:856(Abst)
16. Denninger M-H, Necciari J, Serre-Lacroix E, Sissmann J. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost 1999;25(Suppl 2):41-46
17. Deray G, Brouard K, Bagnis C, et al. Safety and activity of clopidogrel, an antiplatelet agent, in chronic renal failure patients. J Am Soc Nephrol 1995;6(Suppl 1):384(Abst)
18. Pugh RNH, Murray-Lion IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophagcal varices. Br J Surg 1973;60:289-296
19. Savi P, Herbert JM, Ptlieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-532
20. American Heart Association. Heart and Stroke Facts. 1997 Statistical Supplement
21. Cockburn J, Reid AL, Bowman JA, Sanson-Fisher RW. Effects of intervention on antibiotic compliance in patients in general practice. Med J Aust 1987;147:324-328
22. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-1884
23. Detry JM, Block P, De Backer G, Degaute JP. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. Eur J Clin Pharmacol 1995;47:477-481
24. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12:7-15
25. Caplain H, D'Honneur GD, Cariou R. Lack of interaction of aspirin (1000 mg) with chronic clopidogrel in volunteers. Haemostasis 1996;26(Suppl 3):557(Abst)